Sarepta's Gene Therapy Just Got the FDA's Scariest Label
Sarepta's flagship gene therapy just earned the FDA's most severe safety label after patient deaths, while the company simultaneously axed 500 jobs and pivoted its entire strategy. Wall Street somehow cheered. Here's why the story is more complicated than the stock price suggests.
Two patient deaths. A black box warning. And 500 people just lost their jobs.
That's the week Sarepta Therapeutics is having. The company behind Elevidys, the only approved gene therapy for Duchenne muscular dystrophy (DMD), just received the FDA's most serious safety label: a boxed warning for fatal liver failure. On the same day, Sarepta announced it's cutting roughly 500 employees, about 36% of its workforce. For a company that was supposed to be writing the gene therapy playbook, this feels less like a stumble and more like a full identity crisis.
The Label That Changes Everything
A black box warning is the pharmaceutical equivalent of a skull and crossbones on the bottle. It's the FDA's loudest possible alarm short of pulling a drug off the market entirely. And now Elevidys has one.
The warning centers on acute serious liver injury, including fatal acute liver failure. At least two non-ambulatory boys with DMD died after receiving Elevidys, with liver failure setting in within about eight weeks of infusion. A third patient survived a horrific cascade of complications: mesenteric vein thrombosis, bowel ischemia, and portal hypertension.
Beyond the boxed warning, the FDA narrowed Elevidys's approved population. The therapy is now restricted to ambulatory DMD patients (those still able to walk) who are four years or older with a confirmed gene mutation. Non-ambulatory patients, the very kids often most desperate for treatment, are no longer eligible outside of clinical trials. Patients with certain genetic deletions involving exons 8 and/or 9 are flat-out contraindicated because of life-threatening muscle inflammation risk.
Think of it like the FDA drawing a smaller and smaller circle around who can safely receive this therapy. The question is whether that circle is still big enough to sustain a business.
A Revenue Story That's Hard to Spin
Elevidys pulled in $898.7 million in net revenue in 2025, representing nearly half of Sarepta's total commercial sales. That sounds impressive until you zoom into the quarterly trajectory. The first half of the year was a rocket ship: Q1 alone generated $375 million, up 180% year over year. But by Q4, Elevidys revenue had cratered to just .
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
